T2 Biosystems, Inc. (TTOO) Financial Statements (2025 and earlier)

Company Profile

Business Address 101 HARTWELL AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15,68910,32932,24142,18911,03350,805
Cash and cash equivalent15,68910,32922,24516,79311,03350,805
Short-term investments   9,99625,396  
Receivables1,4202,1635,1345,0992,8251,786
Inventory, net of allowances, customer advances and progress billings4,8194,2853,9093,6363,5992,677
Inventory4,8194,2853,9093,6363,5992,677
Other undisclosed current assets3,2612,5823,1102,6601,4381,340
Total current assets:25,18919,35944,39453,58418,89556,608
Noncurrent Assets
Operating lease, right-of-use asset7,3958,7419,76611,0343,360
Property, plant and equipment1,6584,5334,6753,7715,8457,315
Long-term investments and receivables    10,002  
Long-term investments    10,002  
Restricted cash and investments5511,5511,551551180180
Other noncurrent assets 4143153136206206
Total noncurrent assets:9,60814,96816,14525,4949,5917,701
TOTAL ASSETS:34,79734,32760,53979,07828,48664,309
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,4328,56511,1709,57014,9606,817
Accounts payable1,5271,2962,8322,0583,753744
Accrued liabilities4,9057,2698,3387,51211,2076,073
Deferred revenue224172518230285
Debt     42,90242,373
Deferred rent credit      268
Derivative instruments and hedges, liabilities 1,60039  2,4252,142
Contract with customer, liability697
Other undisclosed current liabilities47,8961,352    
Total current liabilities:56,15210,12811,6889,80060,57252,297
Noncurrent Liabilities
Long-term debt and lease obligation  49,65157,14955,7681,873 
Long-term debt, excluding current maturities  49,65147,79045,235  
Liabilities, other than long-term debt6,6819,3544,6054,78446625
Deferred revenue83522842446
Contract with customer, liability133
Deferred rent credit      492
Other liabilities   4,5773,350  
Operating lease, liability6,5988,2149,35910,5331,873
Derivative instruments and hedges, liabilities  1,088 1,010  
Other undisclosed noncurrent liabilities  4,849    
Total noncurrent liabilities:6,68163,85461,75460,5521,919625
Total liabilities:62,83373,98273,44270,35262,49152,922
Equity
Equity, attributable to parent(28,036)(39,655)(12,903)8,726(34,005)11,387
Common stock481661485144
Additional paid in capital556,256494,556459,151431,544342,121328,514
Accumulated other comprehensive income (loss)   (4)9  
Accumulated deficit(584,296)(534,219)(472,216)(422,975)(376,177)(317,171)
Total equity:(28,036)(39,655)(12,903)8,726(34,005)11,387
TOTAL LIABILITIES AND EQUITY:34,79734,32760,53979,07828,48664,309

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues7,19322,30528,05818,1308,33510,500
Cost of revenue(14,460)(21,101)(20,703)(20,759)(16,531)(15,378)
Cost of product and service sold (2,511)(151) (636) (683)
Gross profit:(7,267)1,2047,355(2,629)(8,196)(4,878)
Operating expenses(42,397)(56,400)(50,328)(38,727)(43,862)(40,212)
Operating loss:(49,664)(55,196)(42,973)(41,356)(52,058)(45,090)
Nonoperating income (expense)(413)(6,807)(6,268)(5,442)400619
Other nonoperating income (expense)(495)12520662400619
Interest and debt expense  (6,084)(6,586)(5,518)(36) 
Other undisclosed income from continuing operations before equity method investments, income taxes      
Loss from continuing operations:(50,077)(68,087)(55,827)(52,316)(51,694)(44,471)
Loss before gain (loss) on sale of properties:(55,827)(52,316)(51,694)(44,471)
Other undisclosed net income (loss) 6,0846,5865,518(7,312)(6,682)
Net loss attributable to parent:(50,077)(62,003)(49,241)(46,798)(59,006)(51,153)
Preferred stock dividends and other adjustments  (330)    
Net loss available to common stockholders, diluted:(50,077)(62,333)(49,241)(46,798)(59,006)(51,153)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(50,077)(62,003)(49,241)(46,798)(59,006)(51,153)
Other comprehensive loss   (13)   
Comprehensive loss:(50,077)(62,003)(49,254)(46,798)(59,006)(51,153)
Other undisclosed comprehensive income, net of tax, attributable to parent  4 9  
Comprehensive loss, net of tax, attributable to parent:(50,077)(61,999)(49,254)(46,789)(59,006)(51,153)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: